The Association Between Axillary Lymph Node Metastasis Patterns and Breast Cancer Prognosis
1 other identifier
observational
2,467
1 country
1
Brief Summary
This is a real-world multicentre study to investigate the metastatic pattern of axillary lymph node and its association with breast cancer prognosis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Sep 2025
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 28, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 11, 2025
CompletedFirst Submitted
Initial submission to the registry
December 4, 2025
CompletedFirst Posted
Study publicly available on registry
December 16, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
September 28, 2026
ExpectedDecember 16, 2025
December 1, 2025
13 days
December 4, 2025
December 4, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Disease free survival
Disease-free survival time is defined as the time from the date of axillary lymph node dissection until the date of the first occurrence of local/regional relapse, distant recurrence, contralateral breast cancer, second malignancy and death from any cause.
From the date of ALND until time of event up to 3 years
Secondary Outcomes (2)
Recurrence-free survival
From the date of ALND until time of event up to 3 years
Overall survival
From the date of ALND until time of event up to 3 years
Study Arms (1)
ALND
breast cancer patients receiving axillary lymph mode dissection
Interventions
Eligibility Criteria
Patients were pathologically diagnosed primary invasive breast cancer from October 2013 to December 2023. They had axillary lymph node dissection.
You may qualify if:
- Aged 18 years or older
- Pathologically confirmed invasive primary breast cancer
You may not qualify if:
- De novo stage IV breast cancer
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Wenjin Yinlead
Study Sites (1)
Renji Hospital, School of Medicine, Shanghai Jiaotong University
Shanghai, 200127, China
Study Officials
- PRINCIPAL INVESTIGATOR
Wenjin Yin, M.D.
Renji Hospital, School of Medicine, Shanghai Jiao Tong University
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR INVESTIGATOR
- PI Title
- Deputy Chief of Breast Surgery Department
Study Record Dates
First Submitted
December 4, 2025
First Posted
December 16, 2025
Study Start
September 28, 2025
Primary Completion
October 11, 2025
Study Completion (Estimated)
September 28, 2026
Last Updated
December 16, 2025
Record last verified: 2025-12